KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non-Current Debt: 2020-2025

Historic Non-Current Debt for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $11.9 million.

  • Recursion Pharmaceuticals' Non-Current Debt fell 41.97% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 41.97%. This contributed to the annual value of $19.0 million for FY2024, which is 1627.70% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Non-Current Debt stood at $11.9 million, which was down 16.16% from $14.2 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Non-Current Debt's 5-year high stood at $22.9 million during Q2 2024, with a 5-year trough of $536,000 in Q4 2022.
  • For the 3-year period, Recursion Pharmaceuticals' Non-Current Debt averaged around $10.1 million, with its median value being $11.9 million (2025).
  • Its Non-Current Debt has fluctuated over the past 5 years, first plummeted by 94.45% in 2021, then soared by 1,884.50% in 2024.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Non-Current Debt stood at $633,000 in 2021, then fell by 15.32% to $536,000 in 2022, then soared by 105.41% to $1.1 million in 2023, then surged by 1,627.70% to $19.0 million in 2024, then plummeted by 41.97% to $11.9 million in 2025.
  • Its Non-Current Debt stands at $11.9 million for Q3 2025, versus $14.2 million for Q2 2025 and $16.4 million for Q1 2025.